Article Text

Download PDFPDF
Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case
  1. D H Smith1,
  2. P Fenn2,
  3. M Drummond3
  1. 1Kaiser Permanente, Center for Health Research, Portland Oregon, USA, Centre for Health Economics, University of York, York, UK
  2. 2Nottingham University Business School, Nottingham, UK
  3. 3Centre for Health Economics, University of York, York, UK
  1. Correspondence to: David H Smith Center for Health Research, Kaiser Permanente Northwest, 3800 N Interstate Ave, Portland, OR 97211, USA; David.Smithkpchr.org

Abstract

Aim: To estimate the potential cost effectiveness of photodynamic therapy (PDT) with verteporfin in the UK setting.

Methods: Using data from a variety of sources a Markov model was built to produce estimates of the cost effectiveness (incremental cost per quality adjusted life year (QALY) and incremental cost per vision year gained) of PDT for two cohorts of patients (one with starting visual acuity (VA) of 20/40 and one at 20/100) with predominantly classic choroidal neovascular disease over a 2 year and 5 year time horizon. A government perspective and a treatment cost only perspective were considered. Probabilistic and one way sensitivity analyses were undertaken.

Results: From the government perspective, over the 2 year period, the expected incremental cost effectiveness ratios range from £286 000 (starting VA 20/100) to £76 000 (starting VA 20/40) per QALY gained and from £14 000 (20/100) to £34 000 (20/40) per vision year gained. A 5 year perspective yields incremental ratios less than £5000 for vision years gained and from £9000 (20/40) to £30 000 (20/100) for QALYs gained. Without societal or NHS cost offsets included, the 2 year incremental cost per vision year gained ranges from £20 000 (20/100) to £40 000 (20/40), and the 2 year incremental cost per QALY gained ranges from £412 000 (20/100) to £90 000 (20/40). The 5 year time frame shows expected costs of £7000 (20/40) to £10 000 (20/100) per vision year gained and from £38 000 (20/40) to £69 000 (20/100) per QALY gained.

Conclusion: This evaluation suggests that early treatment (that is, treating eyes at less severe stages of disease) with PDT leads to increased efficiency. When considering only the cost of therapy, treating people at lower levels of visual acuity would probably not be considered cost effective. However, a broad perspective that incorporates other NHS treatment costs and social care costs suggests that over a long period of time, PDT may yield reasonable value for money.

  • AMD, age related macular degeneration
  • CNV, choroidal neovascularisation
  • PDT, photodynamic therapy
  • QALY, quality adjusted life year
  • VA, visual acuity
  • age related macular degeneration
  • blindness
  • cost effectiveness
  • verteporfin
  • AMD, age related macular degeneration
  • CNV, choroidal neovascularisation
  • PDT, photodynamic therapy
  • QALY, quality adjusted life year
  • VA, visual acuity
  • age related macular degeneration
  • blindness
  • cost effectiveness
  • verteporfin

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Funding: This study was sponsored by Novartis AG, Switzerland. The contract gave full rights of publication to the investigators.

  • Series editors: Melissa and Gary Brown

Linked Articles

  • BJO at a glance
    Creig Hoyt